Latest Conference Articles

December 9th 2024, 2:00pm

ASH Annual Meeting and Exposition

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

December 9th 2024, 1:00pm

ASH Annual Meeting and Exposition

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

December 9th 2024, 2:23am

OncLive News Network: On Location at ASH 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

December 9th 2024, 1:30am

ASH Annual Meeting and Exposition

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

December 9th 2024, 1:30am

ASH Annual Meeting and Exposition

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

December 8th 2024, 11:11pm

ASH Annual Meeting and Exposition

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

December 8th 2024, 10:25pm

ASH Annual Meeting and Exposition

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

December 8th 2024, 9:55pm

ASH Annual Meeting and Exposition

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.

December 8th 2024, 9:45pm

ASH Annual Meeting and Exposition

Social determinants of health have a more pronounced effect on mortality among patients with AML who did not receive transplant vs those who did.

December 8th 2024, 9:29pm

ASH Annual Meeting and Exposition

Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.

December 8th 2024, 9:17pm

ASH Annual Meeting and Exposition

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia

December 8th 2024, 9:10pm

ASH Annual Meeting and Exposition

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

December 8th 2024, 8:50pm

ASH Annual Meeting and Exposition

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

December 8th 2024, 8:43pm

ASH Annual Meeting and Exposition

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

December 8th 2024, 8:23pm

ASH Annual Meeting and Exposition

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

December 8th 2024, 7:42pm

ASH Annual Meeting and Exposition

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

December 8th 2024, 6:42pm

ASH Annual Meeting and Exposition

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

December 8th 2024, 4:53pm

ASH Annual Meeting and Exposition

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

December 8th 2024, 4:00am

ASH Annual Meeting and Exposition

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

December 8th 2024, 2:57am

ASH Annual Meeting and Exposition

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.